Details for: KYNMOBI
Company: SUNOVION PHARMACEUTICALS CANADA INC
DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
---|---|---|---|---|---|
02500264 | KYNMOBI | APOMORPHINE HYDROCHLORIDE | 10 MG / FILM | FILM, SOLUBLE | SUBLINGUAL |
02500272 | KYNMOBI | APOMORPHINE HYDROCHLORIDE | 15 MG / FILM | FILM, SOLUBLE | SUBLINGUAL |
02500280 | KYNMOBI | APOMORPHINE HYDROCHLORIDE | 20 MG / FILM | FILM, SOLUBLE | SUBLINGUAL |
02500299 | KYNMOBI | APOMORPHINE HYDROCHLORIDE | 25 MG / FILM | FILM, SOLUBLE | SUBLINGUAL |
02500302 | KYNMOBI | APOMORPHINE HYDROCHLORIDE | 30 MG / FILM | FILM, SOLUBLE | SUBLINGUAL |
Summary Reports
Consumer Information
This information was provided by the drug’s manufacturer when this drug product was approved for sale in Canada. It is designed for consumers and care givers. It is a summary of information about the drug and will not tell you everything about the drug. Contact your doctor or pharmacist if you have any questions about the drug.
What the medication is used for
KYNMOBI is used, as needed, to treat OFF episodes in adults with Parkinson’s disease. An OFF episode is when your Parkinson’s movement symptoms (e.g., tremor, slowness, stiffness and difficulty moving) are unexpectedly not controlled by your regular Parkinson’s medication. KYNMOBI is for use with other drugs to treat Parkinson’s disease and does not replace the other drugs prescribed by your doctor to treat your Parkinson’s symptoms.
What it does
KYNMOBI belongs to a group of drugs called dopamine agonists. It is not known exactly how it works. It seems to improve some of the chemical imbalance in the part of the brain affected by Parkinson’s disease.
When it should not be used
What the medicinal ingredient is
Apomorphine hydrochloride
What the non-medicinal ingredients are
ammonia, butyl alcohol, dehydrated alcohol, disodium EDTA dihydrate, FD&C Blue #1, glycerin (natural), glyceryl monostearate, hydroxyethyl cellulose, hydroxypropyl cellulose, isopropyl alcohol, maltodextrin, menthol crystals, potassium hydroxide, propylene glycol, pyridoxine hydrochloride, shellac, sodium hydroxide, sodium metabisulfite, sucralose and titanium dioxide.
What dosage form it comes in
Soluble films of 10 mg, 15 mg, 20 mg, 25 mg and 30 mg
Warnings and precautions
You can suddenly fall asleep without any warning while taking KYNMOBI. You should
not:
You may put yourself and others at risk for serious injury or death.
If this happens to you, contact your doctor right away.
Falling asleep suddenly without warning has been reported in patients taking other
similar drugs to treat Parkinson’s disease.
To help avoid side effects and ensure proper use, talk to your healthcare professional before you take KYNMOBI. Talk about any health conditions or problems you may have, including if you:
- Have difficulty staying awake during the daytime
- Have suspicious, undiagnosed changed patches of pigmented skin, including irritated or irregular moles, or moles in which you have noticed changes or a history of skin cancer (melanoma)
- Have dizziness
- Have fainting spells
- Have asthma
- Have a history of fibrosis
- Are allergic to any medicines containing sulfites
- Have severe uncontrolled involuntary movements that can look like fidgeting, writhing or swaying called dyskinesia
- Have liver or kidney problems
- Have any unusual conditions related to your eyes or eyesight
- Have had a stroke or other brain problems
- Have any mental disorders or have seen or heard things that are not there (hallucinations)
- Drink alcohol
- Are pregnant or plan to become pregnant. It is not known if KYNMOBI will harm your unborn baby. KYNMOBI should not be used if you are pregnant.
- Are breastfeeding or plan to breastfeed. It is not known if KYNMOBI passes into your breast milk. You and your healthcare provider should decide if you will take KYNMOBI or breastfeed. You should not do both.
- KYNMOBI can cause problems with your heart rhythm called QTc prolongation. You may have no symptoms or you may have dizziness, feeling like your heart has skipped or added a beat, fainting or seizures. If these symptoms continue, they can lead to sudden death. You may be more at risk if you have had or have:
- a heart attack
- congestive heart failure
- an irregular heartbeat or heart rhythm
- a blockage in one or more of your arteries that affects blood flow to your heart
- an abnormally rapid heart rate
- heart palpitations (feeling like your heart has skipped a beat or added an extra beat)
- a family history of sudden cardiac death at less than 50 years of age
- problems of electrocardiogram (ECG) abnormality called “Long QT syndrome”
- diabetes
- imbalances in the electrolytes in your body (potassium, magnesium and calcium)
- KYNMOBI may cause low blood pressure at any time or when you go from sitting or lying down to standing. Your blood pressure may be monitored while you are taking KYNMOBI especially if you are taking medication for high blood pressure, if you have a history of low blood pressure or if you have any heart problems.
- KYNMOBI can cause neuroleptic malignant syndrome. This is a disorder that causes you to have a high fever, confusion, altered states and stiffness in your muscles.
- When reducing your dose of KYNMOBI or stopping treatment, you may have withdrawal symptoms. These include lack of interest, anxiety, depression, fatigue, sweating, panic attacks, insomnia, irritability and pain.
- While taking KYNMOBI, you may have unusual urges and/or behaviors such as excessive:
- gambling
- sexual behavior
- eating
- spending You or your caregiver should tell the doctor if either of you notice that you have new or changes to your behavior.
Other warnings you should know about:
Interactions with this medication
- Diuretics
- Laxatives and enemas
- Certain antibiotics
- High doses of steroids
- antiarrhythmics (such as flecainide and propafenone)
- antipsychotics (such as chlorpromazine and haloperidol)
- antidepressants (such as fluoxetine and amitriptyline)
- opioids (such as methadone)
- some antibiotics (such as erythromycin, clarithromycin and ciprofloxacin)
- antimalarials (such as quinone and chloroquine)
- antifungals (such as ketoconazole)
- kinase inhibitors (such as sunitinib)
- histone deacetylase inhibitors (such as vorinostat)
- beta-2 adrenoceptor agonists (such as salmeterol)
Proper use of this medication
- you have read and understand these instructions.
- you have reviewed the steps with your healthcare professional on how to take it.
Usual dose: Your doctor will determine the right dose for you. Take it exactly as your doctor has told you to. The usual starting dose of KYNMOBI is 10 mg. Depending on how you respond to KYNMOBI your doctor may increase your dose 5 mg at a time to a maximum of 30 mg.
Take 1 film per OFF episode. Do not take another dose of KYNMOBI sooner than 2 hours after the last dose. Most patients need to take KYNMOBI 2 times a day. Do not take more than 5 films per day.
Do not change your dose of KYNMOBI or use it more often than prescribed unless your doctor has told you to.
Instructions for Use:
Each KYNMOBI soluble film comes in a sealed foil pouch (see Figure A)

Step 2: Open the KYNMOBI foil pouch.




Overdose:
Missed dose:
You should only use KYNMOBI during an OFF episode. If you are unable to take KYNMOBI during an OFF episode, you can take it at your next OFF episode.
Side effects and what to do about them
These are not all the possible side effects you may feel when taking KYNMOBI. If you
experience any side effects not listed here, contact your healthcare professional.
Common side effects of KYNMOBI include:
Symptom / effect | Talk to your healthcare professional Only if severe | Talk to your healthcare professional In all cases | Stop taking drug and get immediate medical help |
---|---|---|---|
VERY COMMON | |||
Oral irritation: redness, numbness, swelling, infection, ulceration, pain or dryness of mouth, lips or tongue | ✔ | ||
COMMON | |||
Falls and injuries from falling | ✔ | ||
Dyskinesia: severe uncontrolled movements | ✔ | ||
Syncope: fainting when standing up | ✔ | ||
Low blood pressure: dizziness, fainting, light-headedness when rising to a sitting or standing position. | ✔ | ||
UNCOMMON | |||
Hallucinations or psychotic-like behavior: seeing or hearing things that are not real, confusion, excessive suspicion, aggressive behavior, agitation, delusional beliefs and disorganized thinking | ✔ | ||
Allergic reaction: hives, itching, rash, swelling of the face, lips, mouth, tongue or throat, trouble breathing and/or swallowing | ✔ | ||
Rare | |||
Compulsive behavior: inability to resist the impulse to perform an action that could be harmful such as gambling too much, increased sexual urges, uncontrollable urge to eat or spend money, or repeating meaningless actions | ✔ | ||
Uneven (irregular) heart beat, palpitation, chest pain and/or discomfort, pain in jaw, shoulders, arm and/or back, shortness of breath, sweating, nausea or lightheadedness | ✔ | ||
Neuroleptic Malignant Syndrome: high fever, confusion, altered states and stiffness in your muscles | ✔ | ||
Skin cancer (melanoma): changed patches of pigmented skin, including irritated or irregular moles, or moles in which you have noticed changes | ✔ | ||
Priapism: prolonged painful erection | ✔ | ||
Excessive sleepiness or falling asleep while doing normal activities | ✔ |
If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.
How to store
Store KYNMOBI at room temperature (15° – 30°C). Keep KYNMOBI in the foil pouch,
protected from light, until ready to use.
Keep out of reach and sight of children.
Reporting side effects
You can report any suspected side effects associated with the use of health products to Health Canada by:
- Visiting the Web page on Adverse Reaction Reporting (https://www.canada.ca/en/healthcanada/services/drugs-health-products/medeffectcanada/adverse-reaction-reporting.html) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.
NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.
More information
If you want more information about KYNMOBI:
This leaflet was prepared by Sunovion Pharmaceuticals Canada Inc.
Last Revised: June 12, 2020